Andrei Thomas‐Tikhonenko

The paper identifies P2RX5 as a new B-cell surface marker and multi-lineage immunotherapy target, showing its expression in B-cell malignancies and T-cell leukemia, and demonstrating the efficacy of P2RX5-directed therapies.

The paper analyzes splicing in 729 pediatric brain tumors, identifies splicing-defined subgroups, and highlights CLK1 exon 4 as an oncofetal event linked to tumor prognosis.

The paper identifies a NRCAM proteoform with skipped microexons as a targetable surface antigen in pHGG and demonstrates its utility in immunotherapy.

This study identifies that the costimulatory domain of CD19-CAR-T cells influences resistance development in B-cell malignancies by affecting CD19 loss and antigen escape.

The paper compares short and long read RNA sequencing technologies, finds they detect different transcriptome features, and introduces software to combine their results for improved analysis.

The paper identifies an alternatively spliced NT5C2 isoform contributing to chemoresistance in B-ALL by enhancing nucleosidase activity and 6-MP resistance.

The paper identifies mutations and RNA-binding proteins affecting CD19 splicing and CART-19 therapy resistance through high-throughput mutagenesis and mathematical modeling.

MOCCASIN corrects known and unknown confounders in RNA splicing analysis using synthetic and real data from TARGET and ENCODE.

The paper investigates the role of SRSF3 in circRNA biogenesis and identifies its impact on circRNA production and potential involvement in hematologic malignancies.